一种新的CGN-RET融合突变对奥西替尼和塞尔帕卡替尼联合治疗有良好反应，导致晚期EGFR突变NCSLC对奥西替尼治疗产生耐药性，病例报告

IF 0.2 Q4 ONCOLOGY Current problems in cancer. Case reports Pub Date : 2023-09-01 DOI:10.1016/j.cpccr.2023.100246

Hamid Mirshahidi , Sue Min Sophia Kwon , Alberto Romagnolo , Kiwon Park , Adam Hagele

{"title":"一种新的CGN-RET融合突变对奥西替尼和塞尔帕卡替尼联合治疗有良好反应，导致晚期EGFR突变NCSLC对奥西替尼治疗产生耐药性，病例报告","authors":"Hamid Mirshahidi , Sue Min Sophia Kwon , Alberto Romagnolo , Kiwon Park , Adam Hagele","doi":"10.1016/j.cpccr.2023.100246","DOIUrl":null,"url":null,"abstract":"<div><p>RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report\",\"authors\":\"Hamid Mirshahidi , Sue Min Sophia Kwon , Alberto Romagnolo , Kiwon Park , Adam Hagele\",\"doi\":\"10.1016/j.cpccr.2023.100246\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.</p></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621923000303\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621923000303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

ret融合是晚期NSCLC患者获得性奥西替尼耐药的已知原因。在这里，我们描述了一个病人谁发展耐奥西替尼的情况下，通过收购一个新的CGN-RET融合突变。她对ret靶向TKI selpercatinib联合奥西替尼治疗有良好的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report

RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊